Analysis of Breast Milk Samples in Lactating Women After Undergoing Botulinum Toxin Injections for Facial Rejuvenation: A Pilot Study.

IF 1.6 3区医学 Q2 SURGERY Facial Plastic Surgery & Aesthetic Medicine Pub Date : 2024-09-01 Epub Date: 2024-02-02 DOI:10.1089/fpsam.2023.0326

Caroline Hudson, Parker Wilson, David Lieberman, Harry Mittelman, Sachin Parikh

{"title":"Analysis of Breast Milk Samples in Lactating Women After Undergoing Botulinum Toxin Injections for Facial Rejuvenation: A Pilot Study.","authors":"Caroline Hudson, Parker Wilson, David Lieberman, Harry Mittelman, Sachin Parikh","doi":"10.1089/fpsam.2023.0326","DOIUrl":null,"url":null,"abstract":"Abstract Background: There are little data on the risk to a breastfeeding infant after facial botulinum toxin injections to the mother. Objective: To detect the presence of botulinum toxin in breast milk from lactating subjects treated with facial botulinum toxin injections, as measured by enzyme-linked immunosorbent assay (ELISA). Methods: For this pilot study, lactating women were injected with standardized facial botulinum toxin type A (BTXA) (range 40-92 U). Collected breast milk samples over 5 days were analyzed for the presence of botulinum toxin. Exclusion criteria included (1) lactating women still using their breast milk for their infant, (2) muscular disorders, (3) any medication that could interfere with neuromuscular function, (4) uncontrolled systemic disease, (5) pregnant, and (6) neuromodulator injection in the past 90 days. Results: Four lactating women were recruited. Eight samples had no BTXA detected, whereas 8 of the 16 total had detectible amounts, which were well below the reported lethal oral dose for an infant. Conclusion: Although the exclusion of lactating women from receiving cosmetic botulinum toxin injections is out of an abundance of caution to the theoretical risk to the infant, this study helps support the notion that facial botulinum toxin injections do not warrant an interruption in breastfeeding. Further studies with larger sample sizes are needed.","PeriodicalId":48487,"journal":{"name":"Facial Plastic Surgery & Aesthetic Medicine","volume":" ","pages":"523-526"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Facial Plastic Surgery & Aesthetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/fpsam.2023.0326","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract Background: There are little data on the risk to a breastfeeding infant after facial botulinum toxin injections to the mother. Objective: To detect the presence of botulinum toxin in breast milk from lactating subjects treated with facial botulinum toxin injections, as measured by enzyme-linked immunosorbent assay (ELISA). Methods: For this pilot study, lactating women were injected with standardized facial botulinum toxin type A (BTXA) (range 40-92 U). Collected breast milk samples over 5 days were analyzed for the presence of botulinum toxin. Exclusion criteria included (1) lactating women still using their breast milk for their infant, (2) muscular disorders, (3) any medication that could interfere with neuromuscular function, (4) uncontrolled systemic disease, (5) pregnant, and (6) neuromodulator injection in the past 90 days. Results: Four lactating women were recruited. Eight samples had no BTXA detected, whereas 8 of the 16 total had detectible amounts, which were well below the reported lethal oral dose for an infant. Conclusion: Although the exclusion of lactating women from receiving cosmetic botulinum toxin injections is out of an abundance of caution to the theoretical risk to the infant, this study helps support the notion that facial botulinum toxin injections do not warrant an interruption in breastfeeding. Further studies with larger sample sizes are needed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

分析哺乳期妇女注射肉毒杆菌毒素进行面部年轻化后的母乳样本：一项试点研究。

摘要背景：有关母亲面部注射肉毒杆菌毒素后对哺乳期婴儿的风险的数据很少。研究目的通过酶联免疫吸附试验（ELISA）检测接受过面部肉毒毒素注射治疗的哺乳期受试者母乳中肉毒毒素的含量。研究方法在这项试验性研究中，哺乳期妇女注射了标准的面部肉毒毒素 A 型（BTXA）（范围为 40-92 U）。对 5 天内采集的母乳样本进行肉毒杆菌毒素含量分析。排除标准包括：(1) 哺乳期妇女仍在使用母乳喂养婴儿；(2) 患有肌肉疾病；(3) 服用任何可能干扰神经肌肉功能的药物；(4) 未受控制的全身性疾病；(5) 怀孕；(6) 在过去 90 天内注射过神经调节剂。结果招募了四名哺乳期妇女。其中 8 个样本未检测到 BTXA，而 16 个样本中有 8 个样本检测到 BTXA，其含量远低于报告的婴儿致死口服剂量。结论：虽然排除哺乳期妇女接受肉毒杆菌毒素美容注射是出于对婴儿理论风险的谨慎考虑，但这项研究有助于支持面部肉毒杆菌毒素注射无需中断母乳喂养的观点。我们还需要进行样本量更大的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊